Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VOR Stock Summary
In the News
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.
Vor Bio Announces Q4 And FY 2022 Results
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.
VOR Financial details
VOR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.94 | -1.25 | -2.06 | -2.29 | -1.75 | |
Operating cash flow per share | -0.81 | -1.05 | -2.07 | -2.15 | -1.49 | |
Free cash flow per share | -0.87 | -1.17 | -2.18 | -2.37 | -1.51 | |
Cash per share | 0.53 | 1.4 | 6.21 | 5.82 | 2.04 | |
Book value per share | 0.63 | 1.39 | 6.47 | 6.34 | 2.24 | |
Tangible book value per share | 0.63 | 1.39 | 6.47 | 6.34 | 2.24 | |
Share holders equity per share | 0.63 | 1.39 | 6.47 | 6.34 | 2.24 | |
Interest debt per share | 0.05 | 0.53 | 0.54 | 0.95 | 0.53 | |
Market cap | 457.81M | 1.3B | 388.49M | 263.02M | 151.18M | |
Enterprise value | 451.34M | 1.27B | 286.71M | 244.22M | 155.48M | |
P/E ratio | -39.99 | -29.98 | -5.65 | -2.9 | -1.28 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -46.45 | -35.79 | -5.62 | -3.09 | -1.51 | |
PFCF ratio | -43.18 | -32.11 | -5.32 | -2.81 | -1.49 | |
P/B Ratio | 59.92 | 26.91 | 1.8 | 1.05 | 1 | |
PTB ratio | 59.92 | 26.91 | 1.8 | 1.05 | 1 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -44.37 | -29.69 | -4.24 | -2.69 | -1.27 | |
EV to operating cash flow | -45.8 | -34.96 | -4.15 | -2.87 | -1.55 | |
EV to free cash flow | -42.57 | -31.36 | -3.93 | -2.61 | -1.53 | |
Earnings yield | -0.03 | -0.03 | -0.18 | -0.35 | -0.78 | |
Free cash flow yield | -0.02 | -0.03 | -0.19 | -0.36 | -0.67 | |
Debt to equity | 0 | 0.38 | 0.08 | 0.16 | 0.24 | |
Debt to assets | 0 | 0.24 | 0.07 | 0.13 | 0.17 | |
Net debt to EBITDA | 0.64 | 0.71 | 1.51 | 0.21 | -0.04 | |
Current ratio | 3.45 | 4.81 | 21.12 | 18.06 | 9.04 | |
Interest coverage | -17.13 | 0 | 0 | 70.56 | 0 | |
Income quality | 0.91 | 0.84 | 1 | 0.92 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.08 | 0.11 | 0.06 | 0.1 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -8.22 | -6.88 | -2.72 | -3.35 | -0.31 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.63 | 6.26 | 17.3 | 18.09 | 9.41 | |
ROIC | -1.44 | -0.51 | -0.27 | -0.28 | -0.58 | |
Return on tangible assets | -1.16 | -0.57 | -0.28 | -0.3 | -0.56 | |
Graham Net | 0.35 | 0.6 | 5.42 | 4.59 | 1.16 | |
Working capital | 5.35M | 38.9M | 204.25M | 223.83M | 125.23M | |
Tangible asset value | 7.64M | 48.27M | 216.26M | 250.61M | 150.72M | |
Net current asset value | 5.35M | 21.47M | 188.07M | 188.19M | 81.7M | |
Invested capital | 0 | 0.38 | 0.08 | 0.16 | 0.24 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 365.5K | 1.53M | 1.95M | 1.66M | 1.29M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 2.78K | 621.32 | 126.7 | 72.19 | 85.19 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.13 | 0.59 | 2.88 | 5.06 | 4.28 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.5 | -0.9 | -0.32 | -0.36 | -0.78 | |
Capex per share | -0.06 | -0.12 | -0.12 | -0.21 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.58 | -0.4 | -0.45 | -0.49 | -0.39 | |
Operating cash flow per share | -0.46 | -0.37 | -0.36 | -0.41 | -0.35 | |
Free cash flow per share | -0.47 | -0.37 | -0.37 | -0.42 | -0.36 | |
Cash per share | 5.82 | 3.17 | 2.79 | 2.37 | 2.02 | |
Book value per share | 6.34 | 3.47 | 3.05 | 2.59 | 2.22 | |
Tangible book value per share | 6.34 | 3.47 | 3.05 | 2.59 | 2.22 | |
Share holders equity per share | 6.34 | 3.47 | 3.05 | 2.59 | 2.22 | |
Interest debt per share | 0.96 | 0.55 | 0.56 | 0.54 | 0.53 | |
Market cap | 263.02M | 356.51M | 207.13M | 143.33M | 152.76M | |
Enterprise value | 244.22M | 352.51M | 212.43M | 134.9M | 157.06M | |
P/E ratio | -2.87 | -3.37 | -1.73 | -1.08 | -1.45 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -14.34 | -14.69 | -8.59 | -5.14 | -6.36 | |
PFCF ratio | -14.09 | -14.63 | -8.45 | -5.05 | -6.33 | |
P/B Ratio | 1.05 | 1.55 | 1.01 | 0.82 | 1.01 | |
PTB ratio | 1.05 | 1.55 | 1.01 | 0.82 | 1.01 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -10.14 | -11.92 | -7.33 | -3.82 | -5.77 | |
EV to operating cash flow | -13.31 | -14.53 | -8.81 | -4.84 | -6.54 | |
EV to free cash flow | -13.08 | -14.47 | -8.67 | -4.76 | -6.51 | |
Earnings yield | -0.09 | -0.07 | -0.14 | -0.23 | -0.17 | |
Free cash flow yield | -0.07 | -0.07 | -0.12 | -0.2 | -0.16 | |
Debt to equity | 0.16 | 0.17 | 0.18 | 0.21 | 0.24 | |
Debt to assets | 0.13 | 0.14 | 0.15 | 0.16 | 0.17 | |
Net debt to EBITDA | 0.78 | 0.14 | -0.18 | 0.24 | -0.16 | |
Current ratio | 18.06 | 17.24 | 15.05 | 10.69 | 9.04 | |
Interest coverage | 24.46 | 15.3 | 0 | 0 | 0 | |
Income quality | 0.77 | 0.85 | 0.8 | 0.84 | 0.91 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0 | 0.02 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.51 | -0.11 | -0.13 | 0.33 | -0.12 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.09 | 5.59 | 5.54 | 5.34 | 4.4 | |
ROIC | -0.07 | -0.09 | -0.12 | -0.15 | -0.13 | |
Return on tangible assets | -0.08 | -0.1 | -0.12 | -0.15 | -0.13 | |
Graham Net | 4.59 | 2.46 | 2.09 | 1.65 | 1.15 | |
Working capital | 223.83M | 204.32M | 178.68M | 149.05M | 125.23M | |
Tangible asset value | 250.61M | 230.22M | 204.45M | 174.78M | 150.72M | |
Net current asset value | 188.19M | 169.58M | 144.86M | 116.2M | 81.7M | |
Invested capital | 0.16 | 0.17 | 0.18 | 0.21 | 0.24 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.3M | 2.49M | 2.43M | 1.48M | 1.06M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 52.13 | 103.74 | 120.19 | 56.4 | 82.23 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 1.73 | 0.87 | 0.75 | 1.6 | 1.09 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.11 | -0.15 | -0.19 | -0.17 | |
Capex per share | -0.01 | 0 | -0.01 | -0.01 | 0 |
VOR Frequently Asked Questions
What is Vor Biopharma Inc. stock symbol ?
Vor Biopharma Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VOR
Is Vor Biopharma Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $6. The lowest prediction is $6 and the highest is $6
What is VOR stock prediction ?
What is Vor Biopharma Inc. stock quote today ?
Vor Biopharma Inc. stock price is $2.3505 today.
Is Vor Biopharma Inc. stock public?
Yes, Vor Biopharma Inc. is a publicly traded company.